NLS Pharmaceutics

We design affordable, safe and effective drugs to safeguard and empower the brain throughout all stages of life.

WE´RE NOT CURRENTLY HIRING

[NLS Pharmaceutics @NLSPharma]

https://t.co/VrtUzVlpBi

[NLS Pharmaceutics @NLSPharma]

The merger is complete! 🚀
@NLSPharmaceutics + @Kadimastem = NewCelX (@Nasdaq: NCEL)
A global biotech focused on #ALS, #Diabetes & #Neurodegenerative diseases — combining cell therapy & neuroscience innovation.
#NewCelX #Biotech #Nasdaq

[NLS Pharmaceutics @NLSPharma]

Exciting progress!
NLS Pharmaceutics & Aexon Labs expand the #DOXA platform with the #AEX6xx series — targeting cognition, arousal, & neuroprotection. A strong step toward next-gen #CNS innovation
https://t.co/U3WwtZtDOE

[NLS Pharmaceutics @NLSPharma]

The BIRD Foundation will continue supporting ITOL-102, our joint Diabetes program with @iToleranceBio — now part of NewCelX Ltd. @KadimastemLTD
#NLSPharma #BIRDFoundation #NewCelX #CellTherapy #diabeteschat
https://t.co/bGjOzczANl

[NLS Pharmaceutics @NLSPharma]

@KadimastemLTD (part of #NewCelX) partners with @GeneTarget Biotechnologies to advance gene-edited cell therapies for #ALS & #diabetes.
Together, we’re building the future of regenerative medicine.
Read more ➡️ https://t.co/s5489o5Zgo #CellTherapy #GeneEditing #Innovation

[NLS Pharmaceutics @NLSPharma]

It’s official! ✅ @Nasdaq has approved our merger with @KadimastemLTD .
Closing expected Oct 30, 2025 — forming NewCelX (Nasdaq: NCEL), a global biotech innovator advancing cell & CNS therapies.
#NLSPharmaceutics #Kadimastem #NewCelX #Nasdaq #biotech
https://t.co/2Izpr7hcIL

[NLS Pharmaceutics @NLSPharma]

NLS shareholders approved the merger with @KadimastemLTD✅
Huge milestone cleared before forming NewCelX Ltd. (Nasdaq: NCEL) → a diversified biotech uniting cell therapy & CNS expertise.
https://t.co/mhqhbq0IYK

[NLS Pharmaceutics @NLSPharma]

Exciting news! 🎉 The @SECGov has declared effective our Form F-4 for the planned merger with @Kadimastem.

The combined company, NewCelX, will unite cell therapy & small-molecule innovation to tackle #ALS, #Diabetes, & #CNS disorders.
https://t.co/KOp6YWfR34

[NLS Pharmaceutics @NLSPharma]

🚨 Patent milestone: Our merger partner @KadimastemLTD secures IP protection in Hong Kong for its IsletRx #diabetes program—expanding global coverage after Europe, U.S. & India. Hong Kong = key Asia hub + gateway to China. https://t.co/RgnaAaFFJE

[NLS Pharmaceutics @NLSPharma]

https://t.co/YXsfaBcmYt

[NLS Pharmaceutics @NLSPharma]

Big news! BIRD Foundation greenlights more funding for iTOL-102, our merger partner's diabetes cure-in-progress with @KadimastemLTD & @iTolerance_inc . Plus: our CSO Dr. Eric Konofal is shortlisted for the 2025 Prix Galien for his groundbreaking work in narcolepsy! 🧠💉

[NLS Pharmaceutics @NLSPharma]

We’ve closed the final $1M of our $3M financing! This supports our merger with Kadimastem and advances programs in ALS and diabetes. @KadimastemLTD #biotech #regenerativemedicine
https://t.co/w68DSW12xE

[NLS Pharmaceutics @NLSPharma]

CEO Issues Letter to shareholders: NLS has raised $6M+, cleared all debt, and advanced key clinical programs. The Kadimastem merger is on track as we prepare for ALS and diabetes trials.
🧾 https://t.co/31sCbDOiGf
#Biotech #ALS #Diabetes #CNS

[NLS Pharmaceutics @NLSPharma]

At @ASCPorg NLS Pharmaceutics will present preclinical results showing Mazindol ER reduces both fentanyl reward and withdrawal symptoms in animal models.
A promising non-opioid approach to fighting addiction.
📍Poster #KO-943 | May 29
#CNS #PharmaNews #OpioidCrisis

[NLS Pharmaceutics @NLSPharma]

Exciting news! NLS' KO-943 study shows Mazindol reduces fentanyl-induced reward in animal models! As we prepare for our merger with @KadimastemLTD, Mazindol remains a key focus for future strategic partnerships in addiction treatment. #AddictionResearch #addiction #biotech

[NLS Pharmaceutics @NLSPharma]

NLS has announced the closing of up to $2M equity financing and a $25M equity facility agreement! These financial resources will support our merger with @KadimastemLTD and the advancement of clinical trials for transformative therapies in ALS and diabetes. Exciting times ahead!

[NLS Pharmaceutics @NLSPharma]

NLS Pharmaceutics announces new preclinical data for AEX-2, our groundbreaking dual orexin receptor agonist! 🧠✨ AEX-2 enhances wakefulness & reduces cataplexy—transforming sleep disorder treatments! #innovationquotes https://t.co/GX77dosSt2

[NLS Pharmaceutics @NLSPharma]

👏 Kudos to @KadimastemLTD and @iTolerance_inc ! They completed a pre-IND meeting with the @US_FDA, bringing us closer to a potential cure for Type 1 Diabetes. Exciting times ahead for our future combined company!https://t.co/Nr4RZ7eso3

[NLS Pharmaceutics @NLSPharma]

Big news from NLS Pharmaceutics! We raised $3.2M in a private placement and settled $4M in debt. Plus, we believe we’ve regained Nasdaq compliance!

Full article: https://t.co/RVpkeZGB2n

#nlspharmaceutics #narcolepsy $NLSP

[NLS Pharmaceutics @NLSPharma]

NLS Pharmaceutics (Nasdaq: NLSP) announces 1-for-40 reverse share split effective Sept 27, 2024. Shares will trade under the same symbol “NLSP” but with a new CUSIP.

Full article: https://t.co/GVmdNJQbSz

#nlspharmaceutics #narcolepsy $NLSP